FM888 / Yongzhan Holdings - LARVOL DELTA

Safety, Tolerability, and Pharmacokinetics of Oral FM888 in Healthy Chinese Adults: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, Drug Dev Ind Pharm) - "FM888 demonstrated a favorable safety profile and predictable pharmacokinetics in healthy subjects. These results support the continued clinical development of FM888 and progression to Phase II trials for chronic pain."

Clinical • Journal • PK/PD data • Pain

Different Combinations of Nitrogen and Carbon Sources Influence the Growth and Postbiotic Metabolite Characteristics of Lactiplantibacillus plantarum Strains Isolated from Malaysian Foods. (PubMed, Foods) - "Hence, the effects of different combinations of carbon (glucose, lactose, sucrose and dextrose) and nitrogen (X-SEED Kat, X-SEED Peptone, X-SEED Nucleo Advanced, Nucel875 MG, FM888 and FM902) sources on the growth of six strains of L. plantarum (RG11, RG14, RI11, RS5, TL1 and UL4) and the functional characteristics (bacteriocin inhibitory activity, antioxidant activity and lactic acid concentration) of their respective postbiotic metabolites were investigated in this study...The current study also revealed that fermentation media were an important factor that greatly impacted the functionalities of postbiotic metabolites due to the presence of various bioactive compounds that contributed to high antioxidant and antimicrobial properties. The results of this study will facilitate the subsequent medium design and optimisation for the development and production of specific postbiotic metabolites produced by the respective L. plantarum strain for their applications in various..."

Journal